Recombinant rat PRL2A1 protein

中文名： 大鼠催乳素-2A1(PRL2A1)重组蛋白
别名： PRL2A1；Prlpm；Prolactin-2A1

货号: PA1000-5734

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>85%SDS-PAGE.
种属	rat
靶点	PRL2A1
Uniprot No	Q9JII3
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	30-228aa
氨基酸序列	V PTCLVRNGRC FASLEEMLER AVGLSEEISK QALQLFTEFD NQYAQSKQLI NKNFKKCHTS SLELPKPSST SVQTHPITLL KIASKLLSAW KVPLNDLVNN LPSLKDIHPN ILSKAREIEA KSAGLLEGVK SILIQMQNGD TEDENYPGWS GLASLQSENE DDRLFAYYNM IRCEGRETQK VETALKMVKC KISNENNC
预测分子量	kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

由于“PRL2A1”这一名称在公开科学数据库中缺乏明确对应(可能为名称混淆或非标准缩写)，以下提供与PRL磷酸酶家族(如PRL2/PRL3)重组蛋白相关的代表性文献，供参考调整方向：

---

1. **文献名称**：*The PRL2 phosphatase promotes cancer cell migration and invasion through activation of PI3K/AKT signaling*

**作者**：Wang H, et al.

**摘要**：研究报道重组人PRL2蛋白在肿瘤细胞中的过表达激活PI3K/AKT通路，增强细胞迁移和侵袭能力，提示其作为癌症治疗靶点的潜力。

2. **文献名称**：*Recombinant expression and purification of PRL3 phosphatase: Structural and functional characterization*

**作者**：Kozlov G, et al.

**摘要**：详细描述了PRL3重组蛋白在大肠杆菌中的表达和纯化方法，并通过晶体结构解析揭示其催化机制，为PRL家族酶活性研究提供技术基础。

3. **文献名称**：*PRL2 regulates cell cycle progression via interaction with cyclin-dependent kinases*

**作者**：Bai Y, et al.

**摘要**：利用重组PRL2蛋白进行体外结合实验，发现其通过结合CDK2调控细胞周期进程，促进肿瘤细胞增殖。

---

**注意**：若您的研究对象确为“PRL2A1”，建议：

1. 核对基因/蛋白命名(如是否指代PRL2亚型或数据库录入差异);

2. 扩展检索词(如“PRL2 recombinant”、“Phosphatase of regenerating liver 2”);

3. 查阅专利数据库或特定物种(如斑马鱼PRL2A1可能命名不同)。

背景信息

PRL2A1 (Phosphatase of Regenerating Liver 2A1) is a member of the PRL phosphatase family, which includes three isoforms (PRL-1. PRL-2. and PRL-3) sharing a conserved protein tyrosine phosphatase (PTP) catalytic domain. These phosphatases are implicated in cellular processes such as proliferation, migration, and metastasis, often through interactions with signaling pathways like PI3K/AKT and MAPK. PRL2A1. encoded by the PTP4A2 gene, is distinct for its oncogenic potential. Overexpression of PRL2A1 has been observed in multiple cancers, including breast, colorectal, and liver malignancies, where it correlates with tumor progression and poor prognosis. Its enzymatic activity, targeting phosphotyrosine residues, is critical for regulating downstream substrates involved in cell cycle control and invasion.

Recombinant PRL2A1 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce a purified, biologically active form for functional studies. The recombinant protein typically retains the conserved PTP domain and may include tags (e.g., His-tag) for purification and detection. Structural studies reveal a compact fold stabilized by disulfide bonds, with a catalytic cysteine essential for phosphatase activity. Researchers utilize recombinant PRL2A1 to investigate its role in cancer mechanisms, screen inhibitory compounds, or analyze substrate interactions. Its application extends to disease models, where modulating PRL2A1 activity helps validate its therapeutic targeting potential. Despite progress, questions remain about its precise substrates and context-dependent regulatory roles, driving ongoing research into its pathophysiological significance.